Boehringer Ingelheim’s BI 764532 Receives the US FDA’s Fast Track Designation for Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers
Shots:
- The US FDA has granted FTD to BI 764532 for ES-SCLC & advanced or metastatic epNEC whose disease has progressed following two & one prior lines of treatment incl. Pt-based CT. The therapy is being developed by Boehringer Ingelheim
- Additionally, the P-I first-in-human dose-escalation trial was presented at ASCO 2023 which showed a clinically acceptable safety profile and early efficacy in patients with DLL3+ ES-SCLC and epNECs
- BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager that is designed to identify DLL3 antigen by using OBT’s proprietary OGAP drug discovery platform
Ref: Globenewswire | Image: Boehringer
Related News:- Boehringer Ingelheim and Eli Lilly Receive the US FDA’s Approval of Jardiance (empagliflozin) for Adults with Chronic Kidney Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
